Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth Story

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...

What Pfizer (PFE)'s Monthly GLP-1 Obesity Drug Push Means For Shareholders

Pfizer recently reported positive Phase 2b results for its monthly injectable obesity drug PF-3944, showing up to 12.3% ...

Why Pfizer shares are under pressure despite a Q4 earnings beat

Evan Seigerman, head of healthcare research at BMO Capital Markets, joins 'Money Movers' to discuss Pfizer and Merck's latest ...

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Pfizer beat fourth-quarter estimates as Covid sales fell, pointing to obesity trial progress and cost cuts in its post-Covid ...
Analytics Insight

PFIZER Stock Holds Near $25.86 as Forecast Targets $36.16 Upside

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Pfizer: Messy Q4 Earnings Mask An Improving Business

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.